secwatch.observer — SEC 8-K summary
======================================

Issuer:     KIORA PHARMACEUTICALS INC (KPRX)
CIK:        0001372514
Form:       8-K
Filed at:   2026-04-02T23:59:59+00:00
Accession:  0001372514-26-000028
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiora Pharmaceuticals CDO Eric Daniels to resign April 17; successor search initiated
--------------------------------------------------------------------------------

- Eric J. Daniels resigns as Chief Development Officer effective April 17, 2026, to pursue other opportunities.
- Resignation not due to any disagreement with company's operations, policies, or practices.
- Company has initiated a search for Daniels' successor; CEO thanked Daniels for his contributions.
- Kiora continues enrollment in KIO-301 (ABACUS-2) and KIO-104 (KLARITY) Phase 2 trials.
- Safety reviews cleared for KIO-301 50µg and 100µg dose cohorts; KIO-104 enrollment ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372514/000137251426000028/0001372514-26-000028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372514/000137251426000028/kprx-20260401.htm
  HTML page:      https://secwatch.observer/filing/0001372514-26-000028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer